Abstracts Archive - Page 2067 of 2607 - ACR Meeting Abstracts

Abstract Number: 2506 • 2014 ACR/ARHP Annual Meeting
Decrease in the Number of Peripheral Leukocytes and Neutrophils and Increase of the Percentage of Eosinophils at 4 Week Predict the DAS28-ESR Remission at 24 Weeks after Administration of Tocilizumab
Tamao Nakashita¹, Shinji Motojima² and Akira Jibatake³, ¹[email protected], Kameda Medical Center, Kamogawa-city, Japan, ²[email protected], Kameda Medical Center, Kamogawa City, Japan, ³Depertment of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose : Tocilizumab (TCZ) is a monoclonal anti-IL-6 receptor antibody, and is very effective in controlling RA activity. However we had noticed that the change…
Abstract Number: 2504 • 2014 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate on the Enhanced Clinical Efficacy of Abatacept after 24 Weeks in Rheumatoid Arthritis Patients
Nobunori Takahashi¹, Toshihisa Kojima¹, Yuji Hirano², Yasuhide Kanayama³, Koji Funahashi⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ³Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose Abatacept (ABT), a selective co-stimulation modulator, is the first in a new class of biologic agents for the treatment of rheumatoid arthritis (RA) that…
Abstract Number: 2505 • 2014 ACR/ARHP Annual Meeting
Long-Term Treatment with Tocilizumab (TCZ) Strongly Suppresses Joint Destruction in Biologic-naïve Patients with Rheumatoid Arthritis (RA) Regardless of Inflammation Status
Akira Sagawa, Sagawa Akira Rheumatology Clinic, Sapporo,060-0001, Japan
Background/Purpose: It is still difficult to completely prevent the progression of joint destruction with any of the currently available biologics. It has been reported that…
Abstract Number: 2503 • 2014 ACR/ARHP Annual Meeting
Early Response to Full-Dose Etanercept-Plus-Methotrexate Induction Therapy Predicts Sustained Remission with Reduced-Dose Combination Therapy in Early Rheumatoid Arthritis Patients
Paul Emery¹, Ronald Pedersen², Jack Bukowski³ and Lisa Marshall⁴, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., United Kingdom, Leeds, United Kingdom, ²Specialty Care, Pfizer Inc, Collegeville, PA, ³Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose: In early rheumatoid arthritis (RA), achievement of clinical remission and low disease activity (LDA) limits joint damage and disability.1 Anti-TNF agents are effective in…
Abstract Number: 2502 • 2014 ACR/ARHP Annual Meeting
Ten Year Follow-up Results of Four Dynamic Treat to Target Strategies in Patients with ACPA Negative Rheumatoid Arthritis
I.M. Markusse¹, G. Akdemir², L. Dirven², M. van den Broek², K.H. Han³, H.K Ronday⁴, P.J.S.M. Kerstens⁵, W.F. Lems^6,7, T.W.J. Huizinga² and C.F. Allaart², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, MCRZ hospital, Rotterdam, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rheumatology, VU Medical Center, Amsterdam, Netherlands, ⁷Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose: To determine the optimal treatment strategy in patients with anti-citrullinated protein antibodies (ACPA) negative (‒) rheumatoid arthritis (RA), as it has been suggested that…
Abstract Number: 2501 • 2014 ACR/ARHP Annual Meeting
Indirect Comparison of Tocilizumab and Tofacitinib in Patients with Rheumatoid Arthritis
Stacey Chang¹, Laura Sawyer¹ and Fred Dejonckheere², ¹Symmetron Limited, London, United Kingdom, ²F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: Tocilizumab (TCZ) is a recombinant, humanized, monoclonal antibody directed against the cytokine interleukin-6 receptor, and tofacitinib (Tofa) is an oral, synthetic, disease-modifying antirheumatic drug…
Abstract Number: 2500 • 2014 ACR/ARHP Annual Meeting
Genetic Variation in the TLR5 Locus Is Associated with Anti-TNF Response Among Rheumatoid Arthritis Patients
Jacob Sode^1,2,3, Ulla Vogel⁴, Steffen Bank^5,6, Paal Skytt Andersen⁷, Merete Lund Hetland^8,9, Henning Locht³, Niels H. H. Heegaard^10,11 and Vibeke Andersen^1,5,12,13, ¹Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ²Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen S, Denmark, ³Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, ⁴National Research Centre for the Working Environment, Copenhagen, Denmark, ⁵Medical Department, Viborg Regional Hospital, Viborg, Denmark, ⁶Institute of Human Genetics, University of Aarhus, Aarhus, Denmark, ⁷Microbiology & Infection Control, Statens Serum Institut, Copenhagen S, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ⁹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ¹⁰Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, ¹¹Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense C, Denmark, ¹²Medical Department, Hospital of Southern Jutland Aabenraa, Aabenraa, Denmark, ¹³Odense University Hospital, OPEN (Odense Patient data Explorative Network), Odense, Denmark
Genetic Variation in the TLR5 Locus is Associated with Anti-TNF Response among Rheumatoid Arthritis PatientsBackground/Purpose: In a recent study (paper in press) of Danish rheumatoid…
Abstract Number: 2499 • 2014 ACR/ARHP Annual Meeting
Early Response Indicator early Predicts Clinical Response to Certolizumab in Rheumatoid Arthritis Patients
Massimiliano Cazzato¹, Laura Bazzichi², Stefano Bombardieri³ and Camillo Giacomelli⁴, ¹Internal Medicine, Rheumatology Unit, Pisa, Italy, ²Santa Chiara Hospital, Rheumatology, pisa, Italy, ³Rheumatology Unit, Pisa, Italy, ⁴Rheumatology, pisa, Italy
Background/Purpose In the last few years the introduction of biological agents has radically changed the clinical outcome of patients with Rheumatoid Arthritis (RA). However, no…
Abstract Number: 2498 • 2014 ACR/ARHP Annual Meeting
Characteristics of Responding Versus Non-Responding Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate
Josef Smolen¹, David Collier², Annette Szumski³, Heather Jones⁴ and Lisa Marshall⁵, ¹PsAID taskforce, EULAR, Zurich, Switzerland, ²Amgen, Inc., Thousand Oaks, CA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ⁵Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose While synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) are often effective, treatment with such agents does not adequately control disease activity in all patients.…
Abstract Number: 2497 • 2014 ACR/ARHP Annual Meeting
Correlation Between Time to Switch and Clinical Response Amplitude to Rituximab in Second Line Treatment in Rheumatoid Arthritis Patients with Treatment Failure to Tumor Necrosis Factor Inhibitors: 3-Year Data from Repeat Observational Study
Ioan Ancuta¹, Ruxandra Ionescu², Catalin Codreanu³, Andra Balanescu², Elena Rezus⁴, Maria Suta⁵, Paulina Ciurea⁶, Mihaela Milicescu⁷, Dan Nemes⁸, Codrina Ancuta⁹, Mihai Bojinca¹⁰, Magda Parvu¹¹ and Horatiu Popoviciu¹², ¹“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ³5 Thomas Masaryk Street, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ⁴Rheumatology, Recovering Clinical Hospital, Iasi, Romania, ⁵317 Tomis Str. , Bl. 4A, ap. 3, Constanta Municipal Hospital, Constanta, Romania, ⁶Clinical County Hospital,Craiova, Craiova, Romania, ⁷Rheumatology, "Dr. I. Cantacuzino" Clinical Hospital, Bucharest, Romania, ⁸Rehabilitation and Rheumatology, ”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, ⁹G.T.Popa Center for Biomedical Research, Iasi, Romania, ¹⁰Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ¹¹Rheumatology, Colentina Clinical Hospital, Bucuresti, Romania, ¹²Rheumatology, University of Medicine and Pharmacy Targu Mures, Tg Mures, Romania
Background/Purpose: In recent years we assist to an increasing interest to get more clinical data to improve the control of disease course in rheumatoid arthritis…
Abstract Number: 2496 • 2014 ACR/ARHP Annual Meeting
Predictors of ACR/EULAR Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Boulos Haraoui¹, Maqbool Sheriff², Majed Khraishi³, Michael Starr⁴, John Kelsall⁵, Milton Baker⁶, Regan Arendse⁷, Sanjay Dixit⁸, William Bensen⁹, Philip Baer¹⁰, Rafat Faraawi⁸, Emmanouil Rampakakis¹¹, John S. Sampalis¹¹, Susan Otawa¹², Allen J Lehman¹², Francois Nantel¹³ and May Shawi¹³, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ³Nexus Clinical Research, St John's, NF, Canada, ⁴Montreal General Hospital, Montreal, QC, Canada, ⁵The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶University of Victoria, Victoria, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸McMaster University, Hamilton, ON, Canada, ⁹Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ¹⁰Private Practice, Scarborough, ON, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada
Background/Purpose Early achievement of remission is associated with improved clinical, functional and radiographic outcomes1. Recent recommendations of the Canadian Rheumatology Association dictate that treatment target…
Abstract Number: 2495 • 2014 ACR/ARHP Annual Meeting
Impact of Golimumab on Physical Function and Employability of Patients with Rheumatoid Arthritis: 5-Year Data from 3 Phase III Clinical Trials
Chenglong Han¹, Edward C. Keystone², Roy Fleischmann³, Josef Smolen⁴, Eric L. Matteson⁵, Paul Emery⁶, Mark C Genovese⁷, Timothy A. Gathany¹ and Elizabeth C. Hsia^8,9, ¹Janssen Global Services, LLC., Malvern, PA, ²University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ³Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, ⁴Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁵Rheumatology, Mayo Clinic, Rochester, MN, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Stanford University Medical Center, Palo Alto, CA, ⁸Janssen Research & Development, LLC., Spring House, PA, ⁹University of Pennsylvania, Philadelphia, PA
Background/Purpose: To assess the impact of golimumab (GLM) on physical function and employability in patients with rheumatoid arthritis (RA) with various prior treatment histories, after…
Abstract Number: 2494 • 2014 ACR/ARHP Annual Meeting
Persistence on Single Disease Modifying Anti-Rheumatic Drug Therapy in US Veterans with Rheumatoid Arthritis Is Extremely Rare
Jonathan Kruger¹, Michael Morgan¹, Andreas Reimold², Ted R. Mikuls³, Gail Kerr⁴ and Grant W. Cannon⁵, ¹Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Rheumatology, Dallas VA and Univ of TX Southwestern Med Ct, Dallas, TX, ³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴Rheumatology, Washington DC VA and Georgetown and Howard University, Washington, DC, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Few rheumatoid arthritis (RA) patients are managed successfully with a single disease modifying anti-rheumatic drug (DMARD). This investigation determined the prevalence and clinical…
Abstract Number: 2513 • 2014 ACR/ARHP Annual Meeting
The Monitoring of Infliximab Levels at Early Stages Can Predict the Development of Anti-Infliximab Antibodies in a Cohort of Rheumatoid Arthritis Patients Treated with Infliximab
Chamaida Plasencia-Rodriguez¹, Dora Pascual-Salcedo², Maria Gema Bonilla³, Alejandro Villalba¹, Diana Peiteado¹, Laura Nuño⁴, Pilar Aguado⁵, Teresa Jurado⁶, Emilio Martín-Mola⁷ and Alejandro Balsa⁸, ¹Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²Immunology, La Paz University Hospital, Madrid, Spain, ³Rheumatology Unit, La Paz University Hospital, Madrid, Spain, ⁴Hospital La Paz-IdiPaz, Madrid, Spain, ⁵Rheumatology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁶Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁷Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁸Rheumatology, Hospital La Paz-IdiPaz, Madrid, Spain
Background/Purpose : There is a close association between serum Infliximab (Ifx) levels and the Antibodies To Infliximab (ATI) with the clinical activity in rheumatoid arthritis…
Abstract Number: 2512 • 2014 ACR/ARHP Annual Meeting
Golimumab Therapy Retention Rates in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthritis: Data from the Italian Lorhen Registry
Vittorio Grosso¹, Roberto Gorla², Piercarlo Sarzi-Puttini³, Fabiola Atzeni⁴, Raffaele Pellerito⁵, Enrico Fusaro⁶, Giuseppe Paolazzi⁷, Pier Andrea Rocchetta⁸, Ennio Giulio Favalli⁹, Antonio Marchesoni¹⁰ and Roberto Caporali¹¹, ¹Division of Rheumatology,, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ²Reumatologia, Spedali Civili, Brescia, Italy, ³Rheumatology Unit, University Hospital L Sacco, Milan, Italy, ⁴Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ⁵Rheumatology, Ospedale Mauriziano, Turin, Italy, ⁶Department of Rheumatology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ⁷Rheumatology, Santa Chiara Hospital, Trento, Italy, ⁸Struttura di Reumatologia A.S.O. «SS.Antonio e Biagio e C.Arrigo», Alessandria, Italy, ⁹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ¹⁰Department of Rheumatology, Gaetano Pini Institute, Milano, Italy, ¹¹Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
Golimumab therapy retention rates in patients with rheumatoid arthritis and seronegative spondyloarthritis: data from the Italian LORHEN registry Background/Purpose The efficacy of Golimumab (GLM) treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].